{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:57:06Z","timestamp":1790301426733,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP2AI144244"],"award-info":[{"award-number":["DP2AI144244"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Infectious Diseases Society of America recommends either a fluoroquinolone or a macrolide as a first-line antibiotic treatment for Legionella pneumonia, but it is unclear which antibiotic leads to optimal clinical outcomes. We compared the effectiveness of fluoroquinolone versus macrolide monotherapy in Legionella pneumonia using a systematic review and meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic search of literature in PubMed, Cochrane, Scopus, and Web of Science from inception to 1 June 2019. Randomized controlled trials and observational studies comparing macrolide with fluoroquinolone monotherapy using clinical outcomes in patients with Legionella pneumonia were included. Twenty-one publications out of an initial 2073 unique records met the selection criteria. Following PRISMA guidelines, 2 reviewers participated in data extraction. The primary outcome was mortality. Secondary outcomes included clinical cure, time to apyrexia, length of hospital stay (LOS), and the occurrence of complications. The review and meta-analysis was registered with PROSPERO (CRD42019132901).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-one publications with 3525 patients met inclusion criteria. The mean age of the population was 60.9 years and 67.2% were men. The mortality rate for patients treated with fluoroquinolones was 6.9% (104\/1512) compared with 7.4% (133\/1790) among those treated with macrolides. The pooled odds ratio assessing risk of mortality for patients treated with fluoroquinolones versus macrolides was 0.94 (95% confidence interval, .71\u20131.25, I2 = 0%, P\u2005=\u2005.661). Clinical cure, time to apyrexia, LOS, and the occurrence of complications did not differ for patients treated with fluoroquinolones versus macrolides.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found no difference in the effectiveness of fluoroquinolones versus macrolides in reducing mortality among patients with Legionella pneumonia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa441","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T19:21:19Z","timestamp":1586978479000},"page":"1979-1989","source":"Crossref","is-referenced-by-count":62,"title":["Are Fluoroquinolones or Macrolides Better for Treating <i>Legionella<\/i> Pneumonia? A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"72","author":[{"given":"Annie S","family":"Jasper","sequence":"first","affiliation":[{"name":"William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA"},{"name":"Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson S","family":"Musuuza","sequence":"additional","affiliation":[{"name":"William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA"},{"name":"Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S","family":"Tischendorf","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa W","family":"Stevens","sequence":"additional","affiliation":[{"name":"Informatics, Decision Enhancement, and Analytic Sciences Center of Innovation, Veterans Affairs (VA) Salt Lake City Health Care System, Salt Lake City, Utah, USA"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantini D","family":"Gamage","sequence":"additional","affiliation":[{"name":"National Infectious Diseases Service, Specialty Care Services, Veterans Health Administration, US Department of Veterans Affairs, Washington, DC, USA"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fauzia","family":"Osman","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasia","family":"Safdar","sequence":"additional","affiliation":[{"name":"William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA"},{"name":"Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"2021072714203383900_CIT0001","volume-title":"Disease Surveillance Summary Report, United States, 2014\u20132015","year":"2018"},{"key":"2021072714203383900_CIT0002","volume-title":"National Notifiable Diseases Surveillance System, 2016 Annual Tables of Infectious Disease Data","year":"2017"},{"key":"2021072714203383900_CIT0003","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.15585\/mmwr.mm6442a2","article-title":"Active bacterial core surveillance for Legionellosis\u2014United States, 2011\u20132013","volume":"64","author":"Dooling","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021072714203383900_CIT0004","doi-asserted-by":"crossref","first-page":"584","DOI":"10.15585\/mmwr.mm6622e1","article-title":"Vital signs: health care\u2013associated Legionnaires\u2019 disease surveillance data from 20 states and a large metropolitan area\u2014United States, 2015","volume":"66","author":"Soda","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021072714203383900_CIT0005","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1086\/342903","article-title":"Trends in Legionnaires disease, 1980\u20131998: declining mortality and new patterns of diagnosis","volume":"35","author":"Benin","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2021072714203383900_CIT0006","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1093\/cid\/civ157","article-title":"The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia","volume":"60","author":"Gershengorn","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021072714203383900_CIT0007","doi-asserted-by":"crossref","first-page":"e180230","DOI":"10.1001\/jamanetworkopen.2018.0230","article-title":"Legionnaires disease surveillance in US Department of Veterans Affairs medical facilities and assessment of health care facility association","volume":"1","author":"Gamage","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2021072714203383900_CIT0008","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF03256652","article-title":"Legionnaire\u2019s disease: update on epidemiology and management options","volume":"2","author":"Sabri\u00e0","year":"2003","journal-title":"Am J Respir Med"},{"key":"2021072714203383900_CIT0009","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-6143.2011.03938.x","article-title":"Legionellosis\u2014United States, 2000\u20132009","volume":"12","author":"Hicks","year":"2012","journal-title":"Am J Transplant"},{"key":"2021072714203383900_CIT0010","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1017\/S0950268811002858","article-title":"Direct healthcare costs of selected diseases primarily or partially transmitted by water","volume":"140","author":"Collier","year":"2012","journal-title":"Epidemiol Infect"},{"key":"2021072714203383900_CIT0011","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jac\/43.6.747","article-title":"The treatment of Legionnaires\u2019 disease","volume":"43","author":"Dedicoat","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2021072714203383900_CIT0012","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.amjmed.2017.06.029","article-title":"Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis","volume":"130","author":"Singh","year":"2017","journal-title":"Am J Med"},{"key":"2021072714203383900_CIT0013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","article-title":"Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions","volume":"26","author":"Leone","year":"2003","journal-title":"Drug Saf"},{"key":"2021072714203383900_CIT0014","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3201\/eid0906.020385","article-title":"Fluoroquinolone use and Clostridium difficile-associated diarrhea","volume":"9","author":"McCusker","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"2021072714203383900_CIT0015","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1093\/clind\/21.Supplement_3.S265","article-title":"Antimicrobial chemotherapy for Legionnaires\u2019 disease: a review","volume":"21(","author":"Edelstein","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2021072714203383900_CIT0016","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkg191","article-title":"Legionnaires\u2019 disease: a rational approach to therapy","volume":"51","author":"Roig","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2021072714203383900_CIT0017","first-page":"203","article-title":"Retrospective analysis of azithromycin versus fluoroquinolones for the treatment of legionella pneumonia","volume":"39","author":"Nagel","year":"2014","journal-title":"Pharmacy and Therapeutics"},{"key":"2021072714203383900_CIT0018","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/428049","article-title":"Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides","volume":"40","author":"Bl\u00e1zquez Garrido","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021072714203383900_CIT0019","author":"Centers for Disease Control and Prevention","year":"2018"},{"key":"2021072714203383900_CIT0020","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/jac\/dku159","article-title":"Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis","volume":"69","author":"Burdet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021072714203383900_CIT0021","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"2021072714203383900_CIT0022","author":"Jasper"},{"key":"2021072714203383900_CIT0023","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2021072714203383900_CIT0024","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"2021072714203383900_CIT0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"2021072714203383900_CIT0026","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2021072714203383900_CIT0027","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/26.suppl_B.129","article-title":"Comparison of the activity of three antibiotic regimens in severe Legionnaires\u2019 disease","volume":"26(Suppl B)","author":"Dournon","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"2021072714203383900_CIT0028","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1183\/09031936.95.08121999","article-title":"Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin","volume":"8","author":"Lode","year":"1995","journal-title":"Eur Respir J"},{"key":"2021072714203383900_CIT0029","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00134-002-1304-8","article-title":"Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy","volume":"28","author":"Gacouin","year":"2002","journal-title":"Intens Care Med"},{"key":"2021072714203383900_CIT0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0149-2918(02)85136-0","article-title":"A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia","volume":"24","author":"Sokol","year":"2002","journal-title":"Clin Ther"},{"key":"2021072714203383900_CIT0031","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/378406","article-title":"Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults","volume":"38","author":"Fogarty","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021072714203383900_CIT0032","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijantimicag.2004.07.013","article-title":"Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization","volume":"25","author":"Querol-Ribelles","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"2021072714203383900_CIT0033","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/428059","article-title":"Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy","volume":"40","author":"Mykietiuk","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021072714203383900_CIT0034","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1378\/chest.128.3.1401","article-title":"Fluoroquinolones vs macrolides in the treatment of Legionnaires disease","volume":"128","author":"Sabri\u00e0","year":"2005","journal-title":"Chest"},{"key":"2021072714203383900_CIT0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1157\/13089688","article-title":"[Treatment for Legionnaires\u2019 disease: macrolides or quinolones?]","volume":"24","author":"Falc\u00f3","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2021072714203383900_CIT0036","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2169\/internalmedicine.46.6006","article-title":"Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia","volume":"46","author":"Haranaga","year":"2007","journal-title":"Intern Med"},{"key":"2021072714203383900_CIT0037","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jinf.2009.06.008","article-title":"The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila","volume":"59","author":"Nakamura","year":"2009","journal-title":"J Infect"},{"key":"2021072714203383900_CIT0038","first-page":"495","article-title":"Macrolides versus quinolones in Legionella pneumonia: results from the community-acquired pneumonia organization international study","volume":"14","author":"Griffin","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021072714203383900_CIT0039","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MD.0b013e31827f6104","article-title":"Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years","volume":"92","author":"Viasus","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"2021072714203383900_CIT0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.medin.2012.05.010","article-title":"Community-acquired Legionella pneumonia in the intensive care unit: impact on survival of combined antibiotic therapy","volume":"37","author":"Rello","year":"2013","journal-title":"Med Intensiva"},{"key":"2021072714203383900_CIT0041","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/jac\/dkx007","article-title":"Antimicrobial strategy for severe community-acquired Legionnaires\u2019 disease: a multicentre retrospective observational study","volume":"72","author":"Cecchini","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021072714203383900_CIT0042","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.cmi.2017.02.030","article-title":"Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis","volume":"23","author":"Garcia-Vidal","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2021072714203383900_CIT0043","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jmii.2017.08.018","article-title":"Community-acquired Legionnaires\u2019 disease at a medical center in northern Taiwan","volume":"52","author":"Kao","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"2021072714203383900_CIT0044","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jmii.2016.08.006","article-title":"Legionnaires\u2019 disease at a medical center in southern Taiwan","volume":"51","author":"Hung","year":"2018","journal-title":"J Microbiol Immunol Infect"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa441\/33386172\/ciaa441.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/11\/1979\/39349175\/ciaa441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/11\/1979\/39349175\/ciaa441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T16:22:34Z","timestamp":1627402954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/11\/1979\/5820714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,4,16]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa441","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,4,16]]}}}